Dr. Burns is Founder, President and CEO of Venatorx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development. He has 30 years’ experience in the pharmaceutical ...
Mr. Heyman brings more than 37 years of biopharmaceutical experience in corporate strategy, business development, venture capital, as well as R&D, legal and operational management experience to Venatorx’s Board. ...
Martin joined the AMR Action Fund in August 2021 coming from Boehringer Ingelheim Venture Fund where he worked as Managing Director USA in Cambridge, MA. He served as board ...
Martin joined the AMR Action Fund in August 2021 coming from Boehringer Ingelheim Venture Fund where he worked as Managing Director USA in Cambridge, MA. He served as board director of ArmaGen Technologies, Inc (acquired by JCR Pharma), Tilos Therapeutics Inc. (acquired by Merck & Co Inc.), Sentien Biotechnologies Inc., Abexxa Biologics Inc., Libra Therapeutics Inc. and Rgenta Therapeutics Inc. Martin also serves on the Board of Directors of MassBio.
Martin started his career at BayernKapital in the early 2000s to focus on seed investments in biotechnology companies in Germany. He held several Marketing positions at Solvay Pharmaceuticals and Boehringer Ingelheim in CNS and Oncology and was involved in the launch of various drugs in the CNS space.
Martin holds a PhD in Biology from University of Würzburg and an MBA from FernUniversität Hagen.
Mr. Haines has more than 25 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth, Mr. Haines ...
Henry Skinner, PhD, MJur, is Chief Executive Officer at the AMR Action Fund. Prior to joining the fund, he held leadership positions across the pharmaceutical and venture capital sectors, ...
Henry Skinner, PhD, MJur, is Chief Executive Officer at the AMR Action Fund. Prior to joining the fund, he held leadership positions across the pharmaceutical and venture capital sectors, including serving as Senior Vice President, Venture at Tekla Capital Management and as Deputy Head and Managing Director of the Novartis Venture Fund. In addition, Henry was the CEO of SelectX Pharmaceuticals, which focused on developing small-molecule antimicrobials, and NeoGenesis Pharmaceuticals, which developed a platform for identifying and optimizing drug candidates.
Over the years, he has held Business Development positions at the Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn, and Lexicon Genetics. Henry was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics. He earned a PhD in Microbiology and an MS in Biochemistry from the University of Illinois; an MJur in Health Law, Policy, and Management from Texas A&M; and an MS and a BS in Biology/Biotechnology from Worcester Polytechnic Institute.
You are using a browser that is not supported. Please consider changing your browser |